In collaboration with U. Copenhagen and UPenn, we use a mAb with exquisite cancer-specificity to target cancer-associated O-glycans on CD44v6 expressed on multiple solid tumors. Safety was demonstrated with 3D organotypic mixed skin cancer models. A great example of the cancer-specificity and therapeutic window possible using GO’s antibodies.
